AHS Cancer Control Alberta

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Docosahexaenoic Acid (DHA) for Women With Breast Cancer in the Neoadjuvant Setting

Phase 2

Conditions: Breast Cancer

Interventions: Dietary Supplement: Docosahexaenoic acid (DHA)
Drug: Placebo oral capsule

First Posted Date: 2019-02-05

Last Posted Date: 2019-10-02

Lead Sponsor: AHS Cancer Control Alberta

Target Recruit Count: 52

Registration Number: NCT03831178

Locations: 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada

The UNSCARRed Study: UNresctable Squamous Cell Carcinoma Treated With Avelumab and Radical Radiotherapy

Phase 2

Active, not recruiting

Conditions: Squamous Cell Carcinoma of the Skin

Interventions: Combination Product: Avelumab and Radical radiotherapy

First Posted Date: 2018-11-09

Last Posted Date: 2024-06-14

Lead Sponsor: AHS Cancer Control Alberta

Target Recruit Count: 20

Registration Number: NCT03737721

Locations: 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada

Unilateral Neck Radiotherapy in Head and Neck Cancer

Not Applicable

Recruiting

Conditions: Head and Neck Neoplasms

Interventions: Radiation: Radiotherapy to the bilateral neck lymphatics and tumor bed (radiotherapy to both sides of the neck)
Radiation: Radiotherapy to ipsilateral neck lymphatics and tumor bed (radiotherapy to one side of the neck)

First Posted Date: 2018-08-09

Last Posted Date: 2024-06-12

Lead Sponsor: AHS Cancer Control Alberta

Target Recruit Count: 175

Registration Number: NCT03622164

Locations: 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada

The Breast Cancer & Physical Activity Level (BC-PAL) Pilot Study

Not Applicable

Completed

Conditions: Breast Cancer Survivorship

Interventions: Behavioral: Higher intensity physical activity intervention
Behavioral: Lighter intensity physical activity intervention

First Posted Date: 2018-06-21

Last Posted Date: 2021-01-12

Lead Sponsor: AHS Cancer Control Alberta

Target Recruit Count: 45

Registration Number: NCT03564899

Locations: 🇨🇦
The Rehabilitation, Exercise and Complementary (REACH) center within the Holy Cross Center, Calgary, Alberta, Canada

A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.

Phase 1

Recruiting

Conditions: Papillary Thyroid Cancer

Interventions: Drug: Imatinib Oral Tablet

First Posted Date: 2018-03-19

Last Posted Date: 2024-06-14

Lead Sponsor: AHS Cancer Control Alberta

Target Recruit Count: 18

Registration Number: NCT03469011

Locations: 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada

HIgh Dose Thymoglobulin Instead of Cyclosporine With a Low Dose of Thymoglobulin for GVHD Prophylaxis

Phase 2

Recruiting

Conditions: Relapse
Graft-versus-host-disease

Interventions: Drug: Treatment Arm - high dose ATG
Drug: Control Arm - standard of care

First Posted Date: 2018-03-07

Last Posted Date: 2024-10-07

Lead Sponsor: AHS Cancer Control Alberta

Target Recruit Count: 200

Registration Number: NCT03456817

Locations: 🇨🇦
Tom Baker Cancer Centre/Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta, Canada

Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP)

Phase 2

Active, not recruiting

Conditions: Carcinoma of Unknown Primary

Interventions: Drug: Pembrolizumab Injection

First Posted Date: 2018-01-05

Last Posted Date: 2023-09-13

Lead Sponsor: AHS Cancer Control Alberta

Target Recruit Count: 26

Registration Number: NCT03391973

Locations: 🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
🇨🇦
Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada
🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada

Avelumab With Valproic Acid in Virus-associated Cancer

Phase 2

Active, not recruiting

Conditions: p16 Positive Squamous Cell Carcinoma of the Vagina or Vulva
p16 Positive Squamous Cell Carcinoma of the Anus or Anal Canal
Squamous Cell Carcinoma of the Cervix
Cancer That is Associated With a Chronic Viral Infection
EBER Positive Hodgkins and Non-hodgkins Lymphona
p16 Positive SCCHN
p16 Positive Squamous Cell Carcinoma of the Penis
EBER Positive NPC

Interventions: Drug: Valproic Acid
Biological: Avelumab

First Posted Date: 2017-11-30

Last Posted Date: 2023-10-11

Lead Sponsor: AHS Cancer Control Alberta

Target Recruit Count: 39

Registration Number: NCT03357757

Locations: 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada

A Study to See Whether Stereotactic Body RadioTherapy (SBRT) Can Shrink Tumours Within the Liver Safely

Not Applicable

Conditions: Neoplasm Metastasis
Colonic Neoplasms

Interventions: Radiation: Stereotactic Body Radiation Therapy

First Posted Date: 2017-06-05

Last Posted Date: 2017-06-07

Lead Sponsor: AHS Cancer Control Alberta

Target Recruit Count: 30

Registration Number: NCT03175146

A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use

Phase 1

Recruiting

Conditions: Neuroendocrine Tumors

Interventions: Drug: [68]Ga-HA-DOTATATE

First Posted Date: 2017-05-09

Last Posted Date: 2024-01-30

Lead Sponsor: AHS Cancer Control Alberta

Target Recruit Count: 500

Registration Number: NCT03145857

Locations: 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy